Skip to main content
CCCC logo

CCCC · C4 Therapeutics, Inc.

Track CCCC — free
$2.48 +0.04 (+1.64%) At close · Nov 20
Market Cap
$325.67M
Shares
131.32M
Volume · Nov 20 3.63M Avg daily vol (3M) 2.55M

Price & Indicators

 

Key stats

Close
$2.48
Fri 20 Nov
Open
$2.39
Fri 20 Nov
Average volume, 30 days
3.0M
shares a session
Short interest
46.6M
35.5% of shares · 15.1 days to cover
Day range
$2.32$2.55
Open $2.39 Close $2.48
52-week closing range
$1.71$4.67
Close $2.48 46.9% under the high
Short volume, last session
34%
Last earnings
May 26, 2026
Latest filing
10-Q · Nov 5
Price history
Oct 2020 to Nov 2026

Latest documents

2026
Nov 17
Investor event
Simsidamide shows 53% response rate in heavily pretreated myeloma

C4 Therapeutics reported a 53% response rate for simsidamide at its 100 micrograms recommended Phase II dose in heavily pretreated multiple myeloma patients, with two MRD negative CRs.

4 source passages
C4 is a targeted protein degradation company this study was done in the most heavily pretreated patient population in late-line therapy at our recommended Phase II dose of 100 micrograms We had a 53% response rate with two MRD negative CRs. Open the document at this passage
Nov 9
Investor event
Simsidamide posts 53% response rate in refractory myeloma

C4 Therapeutics reported a 53% overall response rate at the highest simsidamide dose in 72 first-in-human patients. Enrollment is expected to finish in the first quarter of 2027, with combination data guided for mid-year 2027.

4 source passages
welcome to this next five-side chat with C4 Therapeutics. So we can start with the top-line summary, that in a first-in-human study, When we treated 72 patients with simsidamide plus dex, we have an overall response rate of 53% at the highest dose level we've guided that that study will be finished enrollment in the first quarter of 2027 We've guided to data mid-year 2027 from that study from all the cohorts that we've evaluated. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cemsidomide enrollment expected complete in first quarter of 2027

Cemsidomide Phase 2 MOMENTUM enrollment is expected to complete in the first quarter of 2027, with initial investigator-assessed overall response rate data expected in the second half of 2027. CFT8919 will not advance outside Greater China at this time.

Revenue $8.47M ▼ 24.6% Net loss $21.84M Diluted EPS -$0.16
Read from the MD&A section
2 source passages
Enrollment for the Phase 2 MOMENTUM trial is expected to be complete in the first quarter of 2027 with initial investigator-assessed overall response rate data expected in the second half of 2027. Based on the evolving treatment landscape for EGFR mutated NSCLC, capital priorities, and available clinical data to date, we will not advance CFT8919 into the next phase of clinical development outside of Greater China at this time. Open the document at this passage
Nov 5
Current report 8-K
Cemsidomide enrollment on track; cash runway through 2028

C4 Therapeutics expects cash to fund operations to the end of 2028, while cemsidomide’s Phase 2 MOMENTUM enrollment is on track to complete in the first quarter of 2027; third-quarter 2026 revenue was $8.5 million.

Financial results
4 source passages
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the third quarter ended September 30, 2026, as well as recent business highlights. The Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in late-line MM is on track to complete enrollment in the first quarter of 2027. Total revenue for the third quarter of 2026 was $8.5 million, compared to $11.2 million for the third quarter of 2025. C4T expects that its current cash, cash equivalents and marketable securities will fund its operating plan to the end of 2028. Open the document at this passage
Sep 25
Current report 8-K
Regulation FD disclosure, Other events

C4 Therapeutics reported cemsidomide immune activation in 62 RRMM patients and biomarker findings from two patients; the 75 µg dose was declared safe, and cohorts at 75 µg and 100 µg are advancing, with data expected in mid-2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$32.28M
Trailing 12 months
Net income (TTM)
−$91.09M
Trailing 12 months
Revenue growth YoY
-24.6%
Year over year
Operating margin
-315.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$32.42M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+87.5%
Year over year · more shares
Price change (1Y)
+4.2%
Trailing year
Short interest
35.5%
Latest settlement · 15.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −24%
below
Price vs 50-day avg −18%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −19%
trailing
6-month return −43%
trailing
YTD return +30%
this year
Relative strength −34%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
35.47% of shares out · ▲ +9.0% MoM · 15.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
152 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
EPS growth +16%
Y/Y
Free cash flow $-99.3M
Buyback $25.0M
authorized
Balance sheet $74.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −48%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−24% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
35.47% of shares out · ▲ +9.0% MoM · 15.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
152 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 26% Range high $5
vs 200-day avg -24% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
upfront cash payment $20M the second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CCCC
C4 Therapeutics, Inc.
this stock
$325.67M +29.8% +1.0% — 35.5%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
152
% held
104.8%
Net QoQ
+20.0M sh
Top holder
Squadron Capital Manageme…
Held Float
View
Held by Funds
Fund positions
133
View
Short & Settlement
Short Interest Rising
Shares short
46.6M
Days to cover
15.1d
Change
+3.9M sh
View
Short Volume
Short vol %
34%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
121
Value
$361
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
46.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$35.9M
Net income (FY)
$-105.0M
EPS diluted
$-1.27
View
Buybacks
Authorized
$25.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
23

C4 Therapeutics reported a 53% response rate for simsidamide at its 100 micrograms recommended Phase II dose in heavily pretreated multiple myeloma patients, with two MRD negative CRs.

View
Proposed Sales
Value
$122.5K
Shares
45.2K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
C4 Therapeutics Reports Third Qua…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
CCCC -10.1% -19.0% -42.9% -26.4% +29.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -1.6% -9.7% -33.7% -17.7% +28.7%

Capital returns

Buyback program · as of May 29, 2023
Authorized
$25.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1662579 CUSIP 12529R107 13F (30d) 159 filings 142 filers Visit website Investor relations